Novotech Health Holdings

What Novotech Health Holdings does

Novotech Health Holdings is a privately held, full-service Contract Research Organization providing clinical research and scientific advisory services to biotech and biopharma sponsors. Its therapeutic focus spans oncology, liver disease, infectious diseases, rare diseases, CNS and neurology, and cell and gene therapy, with operational reach across more than 50 countries through 7,260+ trial sites and 4,950+ investigators. The company reports a cumulative track record of 4,450+ clinical trials and 60+ drugs supported to market approval, anchored by deep Asia-Pacific delivery infrastructure and multilingual engagement (English, Korean, Chinese, Traditional Chinese).

The core service stack covers the full clinical development lifecycle, including clinical monitoring, data management, biostatistics, regulatory affairs, medical writing, laboratory services, and scientific advisory. A Real World Data platform and status as the first private Institutional Biosafety Committee in Australia for GMO trial approvals represent specialized capabilities in cell and gene therapy and evidence-generation. The firm operates an integrated Site Management Organization through the Acrostar Division and holds the 2025 Asia Pacific Cell & Gene Therapy Award. Strategic partnerships with START (early-phase oncology) and BIO (hepatitis B content) extend its disease-area positioning.

The business model is enterprise clinical services sold on a quote-based, multi-year contract basis to biotech and biopharma sponsors, with named engagements including U.S. CNS biopharma and Japanese biotech sponsors. Pricing is custom per program rather than packaged. Revenue mechanics are tied to full-service study budgets, milestone-based billings across trial phases, and cross-selling of ancillary services (SMO, lab, regulatory). Strategic activity in 2025-2026, including the January 2026 CEO transition to a Singapore-based executive, signals continued investment in Asia-Pacific operational depth and oncology vertical expansion.

Name

Novotech Health Holdings

Legal name

Novotech Health Holdings

Website

https://novotech-holdings.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

1–10 employees

Short description

Novotech Health Holdings is a global full-service Contract Research Organization providing clinical trial services and scientific advisory to biotech and biopharma sponsors, with deep Asia-Pacific expertise across 50+ countries and 4,450+ completed trials.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG)

Keywords

• Clinical research services
• Contract research organization
• Clinical trial management
• Drug development consulting
• Biotechnology research services

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Research Services: Novotech provides comprehensive clinical research services including medical and regulatory consulting, patient recruitment, site management, biometrics, data management, laboratory services, and real-world data solutions. These are project-based or retainer engagements with biotech and biopharma sponsors.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Core offering

Novotech is a full-service global Contract Research Organization (CRO) providing integrated clinical research and scientific advisory services to biotech and biopharma sponsors. Its offerings span the full drug development continuum, including medical and regulatory consulting, patient recruitment and site selection, clinical operations and project management, site management organization (SMO) services via Acrostar, biometrics and data management, bioanalytical laboratory services, real-world data solutions, and specialized therapeutic area expertise across oncology, liver disease, infectious diseases, rare diseases, and cell/gene therapy.

Product overview

Novotech is a globally recognized full-service Contract Research Organization (CRO) offering an integrated portfolio of clinical trial services and therapeutic area expertise. The platform consists of core operational services (Medical and Regulatory Consulting, Patient Recruitment and Site Selection, Clinical Operations and Project Management, Site Management Organization via Acrostar, Biometrics and Data Management, Laboratory Services, and Real World Data solutions) combined with specialized therapeutic area expertise (Oncology, Pharmacometric Services, Drug Development Consulting, GMO Solutions, Liver Disease, Infectious Diseases and Vaccines, Orphan and Rare Diseases, and Clinical and Regulatory Strategy). The FLEX offering provides flexible resourcing for pipeline management. Together, these services enable biotech companies to advance their drug development programs across all clinical phases with geographic reach spanning 50+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• Acrostar: Site Management Organization (SMO) Division operating as part of Novotech for clinical trial site management services
• FLEX

Products and services

• Medical and Regulatory Consulting

Quantifiable outcome

• 4450+ clinical trials executed
• +3 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered core, flagship and minor.

• START (Cancer Therapy)coreStrategic or Co-development Partner · 1 January 2025Strategic partnership to accelerate early-phase oncology trials through collaborative approach. The partnership combines START's oncology expertise with Novotech's global CRO capabilities to advance cancer therapy development.
• BIO (Biotechnology Innovation Organization)flagshipStrategic or Co-development Partner · 1 January 2025Novotech featured in hepatitis B film presented by BIO and produced by BBC StoryWorks, highlighting Novotech's role in advancing hepatitis B drug development. This represents a strategic content partnership to raise awareness of Novotech's capabilities in liver disease clinical trials.
• BBC StoryWorksminorGTM or Marketing Partner · 1 January 2025Co-produced documentary-style film on hepatitis B drug development featuring Novotech. BBC StoryWorks produces content for BIO highlighting innovative biotech companies advancing treatments for global health challenges.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Syneos Health: Syneos Health is a global clinical-to-commercial CRO serving biotech and pharma sponsors across Phase I–IV. Its integrated clinical and commercial model overlaps Novotech's full-service positioning for mid-sized sponsors.
• Medpace Holdings: Medpace is a mid-sized full-service CRO focused on biotech and small-to-mid pharma sponsors, very similar to Novotech's core target customer. It competes with Novotech on Phase II–III trials, though Medpace's geographic mix is more US-centric.
• ICON plc: ICON is a top-tier global full-service CRO with strong biotech sponsor relationships, formed through the PRA Health Sciences merger. It competes head-to-head with Novotech on biotech-sponsored clinical trials and post-2023 has significant global scale, but its APAC site network is less differentiated.
• Parexel International: Parexel is a global full-service CRO with a long-standing focus on biotech and small-to-mid pharma sponsors, the same customer segment Novotech targets. Its service portfolio, therapeutic mix, and biotech GTM motion closely parallel Novotech's positioning.
• Charles River Laboratories: Charles River is a leading CRO/CDMO with strong preclinical-to-clinical services and central lab capabilities. It overlaps Novotech on bioanalytical, central lab, and early-phase clinical services to biotech sponsors, particularly in North America and Europe.
• Tigermed (Hangzhou Tigermed Consulting): Tigermed is one of the largest China-headquartered CROs with growing global reach. It competes with Novotech on clinical operations for Asia-Pacific trials and on biotech sponsor relationships, especially for China-including trial designs.
• WuXi Clinical / WuXi AppTec: WuXi AppTec operates a global CRO/CDMO with a major China-based clinical and bioanalytical footprint. It is one of Novotech's most direct Asia-based CRO competitors, particularly for biotech sponsors running trials that include China sites.

Broad incumbents

• Labcorp Drug Development (formerly Covance): Labcorp's Drug Development division is a global CRO with central lab, bioanalytical, and clinical trial services. It overlaps directly with Novotech on Phase I–III clinical operations and bioanalytical offerings and is a similarly scaled full-service competitor.
• IQVIA: IQVIA is the largest global CRO and life sciences services provider. It competes with Novotech across the full clinical development continuum and offers far broader data, technology, and commercial services, but its APAC depth is more generalist and less specialized than Novotech's biotech CRO focus.

Emerging players

• Clinipace Worldwide: Clinipace is a smaller mid-market CRO with biotech and oncology focus. It competes with Novotech for biotech sponsors needing personalized full-service support, typically on smaller, more specialized oncology and rare disease trials.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubevimeo.com/novotechcro
• Facebookfacebook.com/NovotechCRO
• LinkedInlinkedin.com/company/novotech

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novotech Health Holdings